Rationale and design of the β-blocker in heart failure with normal left ventricular ejection fraction (β-PRESERVE) study

European Journal of Heart Failure

Volumn 12, Issue 2, 2010, Pages 181-185

  Zhou, Jingmin ^a   Shi, Haiming ^a   Zhang, Jian ^a   Lu, Yongxin ^a   Fu, Michael ^a   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Blocker; Chronic heart failure; Left ventricular ejection fraction; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; METOPROLOL SUCCINATE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; ELECTROCARDIOGRAM; FEMALE; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; ENDPOINT DETERMINATION; FEMALE; HEART FAILURE; HUMANS; MALE; METOPROLOL; MULTIVARIATE ANALYSIS; RESEARCH DESIGN; SINGLE-BLIND METHOD; VENTRICULAR FUNCTION, LEFT;

EID: 75149129486     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp193     Document Type: Article

References (16)

1. Fu M. Heart failure therapy in the elderly: where are we? What are we doing? Int J Cardiol 2008;125:147-148.
2. Das A, Abraham S, Deswal A. Advances in the treatment of heart failure with a preserved ejection fraction. Curr Opin Cardiol 2008;23:233-240.
3. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-327.
4. Owan TE, Hodge DO, Herges RMJacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
5. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-269.
6. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurrayJJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators Committees. Effects of candesar-tan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-781.
7. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006;27:2338-2345.
8. Massie BM, Carson PE, McMurray JJV, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;358:2456-2467.
9. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction >40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997;80:207-209.
10. Nodari S, Metra M, Dei Cas L Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003;5:621-627.
11. Bergstrom A, Andersson B, Edner M, Nylander E, Persson H, Dahlstrom U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004;6:453-461.
12. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225.
13. Van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150-2158.
14. Dobre D, van Veldhuisen DJ, DeJongste MJ, Lucas C, Cleuren G, Sanderman R, Ranchor AV, Haaijer-Ruskamp FM. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail 2007;9:280-286. (Pubitemid 46330137)
15. Fu M. p-blocker therapy in heart failure in the elderly. Int J Cardiol 2008;125: 149-153.
16. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.